1.0The Medical Xchangehttps://themedicalxchange.com/en/Debating North American Cholesterol Guidelines and the Role of PCSK9 Inhibitors - The Medical Xchangerich600338<blockquote class="wp-embedded-content" data-secret="KVFjIJVGfY"><a href="https://themedicalxchange.com/en/2015/11/05/2015-canadian-cardiovascular-congress-ccc/">Debating North American Cholesterol Guidelines and the Role of PCSK9 Inhibitors</a></blockquote><iframe sandbox="allow-scripts" security="restricted" src="https://themedicalxchange.com/en/2015/11/05/2015-canadian-cardiovascular-congress-ccc/embed/#?secret=KVFjIJVGfY" width="600" height="338" title="“Debating North American Cholesterol Guidelines and the Role of PCSK9 Inhibitors” — The Medical Xchange" data-secret="KVFjIJVGfY" frameborder="0" marginwidth="0" marginheight="0" scrolling="no" class="wp-embedded-content"></iframe><script type="text/javascript">
/* <![CDATA[ */
/*! This file is auto-generated */
!function(d,l){"use strict";l.querySelector&&d.addEventListener&&"undefined"!=typeof URL&&(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&&!/[^a-zA-Z0-9]/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret="'+t.secret+'"]'),o=l.querySelectorAll('blockquote[data-secret="'+t.secret+'"]'),c=new RegExp("^https?:$","i"),i=0;i<o.length;i++)o[i].style.display="none";for(i=0;i<a.length;i++)s=a[i],e.source===s.contentWindow&&(s.removeAttribute("style"),"height"===t.message?(1e3<(r=parseInt(t.value,10))?r=1e3:~~r<200&&(r=200),s.height=r):"link"===t.message&&(r=new URL(s.getAttribute("src")),n=new URL(t.value),c.test(n.protocol))&&n.host===r.host&&l.activeElement===s&&(d.top.location.href=t.value))}},d.addEventListener("message",d.wp.receiveEmbedMessage,!1),l.addEventListener("DOMContentLoaded",function(){for(var e,t,s=l.querySelectorAll("iframe.wp-embedded-content"),r=0;r<s.length;r++)(t=(e=s[r]).getAttribute("data-secret"))||(t=Math.random().toString(36).substring(2,12),e.src+="#?secret="+t,e.setAttribute("data-secret",t)),e.contentWindow.postMessage({message:"ready",secret:t},"*")},!1)))}(window,document);
//# sourceURL=https://themedicalxchange.com/wp-includes/js/wp-embed.min.js
/* ]]> */
</script>
https://themedicalxchange.com/wp-content/uploads/2015/11/2350_CCC_2015_EN_Fig_1.PNG960720Toronto – Low-density lipoprotein cholesterol (LDL-C) goals for the treatment of dyslipidemia differ among US and Canadian guidelines. At the 2015 CCC, an expert from the US debated with his Canadian counterparts on how goals are best defined on the basis of randomized controlled trials. This debate is timely. Treatment goals, particularly in high-risk patients, are more frequently achieved with PCSK9 inhibitors than with previous options. Defining goals according to risk is an essential step toward the ultimate objective, which is to reduce cardiovascular (CV) morbidity and mortality.